Various factors shape the market dynamics of pharmaceutical insulin syringes that collectively determine their growth and trajectory. Crucially, insulin syringes are used to manage diabetes effectively so that patients can receive an accurate dose of insulin. This market is driven by many things including drivers, challenges, trends and opportunities.
One of the major drivers in the Pharmaceutical Insulin Syringes market is a global rise in diabetes prevalence. The demand for these tools required for administering this substance is also on the increase as there is increasing number of type 1 and type 2 diabetes patients worldwide. It has been noted that as diabetes remains a major public health problem worldwide there will be an increase in the number of individuals diagnosed with diabetes hence the diabetic population as well as its need for insulin syringes.
Market dynamics are influenced by technological advancements regarding insulin syringe designs and manufacturing processes. Continuous innovation centers on making insulin delivery safer and better while simultaneously improving user experience. For instance, patient comfort is enhanced through features such as shorter needles, finer gauge needles, ergonomic designs which contribute to ease of use facilitating patients’ adherence to correct insulin therapy among others. Additionally, development of safety syringes with needlestick injury prevention features is becoming popular.
However, there are several obstacles facing Pharmaceutical Insulin Syringes due to challenges around needle disposal concerning environmental impact considerations being crucial. Proper medicaments’ disposal depends on how usable they remain intact without causing harm to other people’s lives thereby putting off infections caused by sharp objects like needles or pins used in injections meant for various purposes including accessing veins or subunit tissues deeper down any person’s skin besides giving different kinds of treatment which may be referred to as injections into those parts under human skins. Again, growing concerns related to recycling disposable syringe made mostly from plastics where more considerations have raised over faulty structures resulting from them. In response to these challenges, there are researchers who have come up with the best ways of addressing such a crisis through considering eco-friendly materials as well as disposal options that can be sustained.
The other emerging trend in the market is an increasing adoption of insulin pen devices as alternatives to traditional syringes. This means that insulin pens provide ease of use, convenience and discreetness making it preferable for patients. However, while insulin pens are becoming more popular there are still some factors that make pharmaceutical insulin syringes continue thriving like; cost effective nature accessibility and preference by certain patient population.
Additionally, patient education and healthcare policies have a significant impact on the adoption of pharmaceutical insulin syringes influencing market dynamics. These include proper administration techniques, adherence rates relevance awareness campaigns, safe needle disposal initiative among others. Furthermore, availability of affordable insulin needles due to health policies regarding affordable insulins also affects their accessibility and utilization.
Geographically the Pharmaceutical Insulin Syringes market exhibits diverse dynamics. Such regions dominate this sector thereby controlling such markets since they have high cases of diabetes like North America, Europe or Asia Pacific area but there has been increased demand for them in emerging markets where prevalence rates are going up with improved medical infrastructure especially among developing countries indicating rapid change in lifestyle.
Insulin Syringes Market Size was valued at USD 1.7 Billion in 2022. The Insulin Syringes market industry is projected to grow from USD 1.77 Billion in 2023 to USD 2.46 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.20% during the forecast period (2023 - 2032). One of the main market driver propelling market expansion is the rise in prevalence of diabetes.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The market for insulin pens, syringes, pumps, and injectors is expanding as diabetes prevalence rises throughout the world. One of the main causes of the rise in the incidence of diabetes worldwide is the rise in the number of obese individuals, bad eating patterns, physical inactivity, and the rise in the number of elderly people. The Centers for Disease Control and Prevention (CDC) in the US estimated that 34.2 million Americans had diabetes in 2020. The International Diabetes Federation estimates that 537 million adults worldwide had diabetes in 2021; by 2045, that figure would climb to 783 million, fueling the demand for insulin pens, syringes, pumps, and injectors.
Patients' opposition to self-injection is limiting the market for insulin pens, syringes, pumps, and injectors. Some patients experience anxiety because to their fear of needles, which makes them delay getting insulin injections and results in uneven insulin uptake. Before the start of diabetes education programs, it has been predicted that 30% to 50% of patients experience worry or dread related to injection-associated pain, according to a report from the National Center for Biotechnology Information (NCBI). According to the survey, over 28% of patients were reluctant to begin insulin therapy even though it had been prescribed because they lacked confidence in their ability to administer the injections and feared pain from self-injection. The market's expansion is being hampered by people's aversion to injecting themselves because of their phobia of needles.Thus, driving the Insulin Syringes market revenue.
The Insulin Syringes Market segmentation, based on 3/10 CC syringe (0.3ml), 1/2 CC syringe (0.5ml), 1CC syringe (1ml), and others. The 1ml syringe size accounted for the majority of sales in 2021. These syringes have a 2-unit graduation and are suitable for dosages larger than 50 units. An adult who needs a substantial dose of insulin may benefit from using a 1 mL syringe.
The Insulin Syringes Market segmentation, based on Disease, includes Type 1 Diabetes and Type 2 Diabetes. In 2022, the insulin syringes market's greatest revenue share was attributed to Type 2 Diabetes. The global prevalence of type-2 diabetes is rising, which is the cause of this. The World Health Organization estimates that around 462 million people, or 6.28 percent of the world's population, had type 2 diabetes in 2019.
The Insulin Syringes Market segmentation, based on end-use includes Hospitals & Clinics, Homecare Settings, and others. The hospital & clinics segment generated the largest revenue share in the insulin syringes market as a result of the rising incidence of chronic diseases like diabetes and obesity in the population. The constantly growing older population also contributes considerably to the growth of the insulin syringe market. According to the American Diabetes Association, 34.2 million people received a diagnosis of diabetes in 2019, with 14.3 million of those over 65 years old being affected.
By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Insulin Syringes Market dominated this market in 2022 (45.80%). This is due to elements including a high prevalence of diabetes, a sophisticated healthcare system, and a significant need for diabetic care supplies. The region has a strong market for insulin syringes and other diabetes treatment goods due to its well-developed healthcare system and substantial diabetic patient population. Further, the U.S. Insulin Syringes market held the largest market share, and the Canada Insulin Syringes market was the fastest growing market in the North America region.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: Insulin Syringes Market SHARE BY REGION 2022 (USD Billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe Insulin Syringes market accounts for the second-largest market share. Another significant market for insulin syringes is Europe. With a highly developed healthcare system, nations like Germany, France, and the United Kingdom have a high prevalence of diabetes. The demand for diabetes management items, especially insulin syringes, is influenced by the region's focus on medical developments, insurance regulations, and patient education.Further, the German Insulin Syringes market held the largest market share, and the UK Insulin Syringes market was the fastest growing market in the European region
The Asia-Pacific Insulin Syringes Market is expected to grow at the fastest CAGR from 2023 to 2032. Due to the rising prevalence of diabetes, especially in China and India, the Asia Pacific region is expected to have considerable growth in the insulin syringes market. The number of diabetic patients is on the rise, which can be attributed to rapid urbanization, changing lifestyles, and aging populations. The need for diabetes management items, particularly insulin syringes, is projected to rise in this region as healthcare infrastructure and awareness improve.Moreover, China’s Insulin Syringes market held the largest market share, and the Indian Insulin Syringes market was the fastest growing market in the Asia-Pacific region.
Insulin Syringes Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the Insulin Syringes market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Insulin Syringes industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Insulin Syringes industry to benefit clients and increase the market sector. In recent years, the Insulin Syringes industry has offered some of the most significant advantages to medicine. Major players in the Insulin Syringes market, including Novo Nordisk A/S, Biocon Ltd, Abbott Laboratories, Terumo Corporation, Cardinal Health Inc., Beckton and Dickinson Company, Eli Lilly and Company, Nipro Medical Corporation, Medline Industries, and Hindustan Syringe and Medical Device Ltd are just a few of the companies that are involved in the pharmaceutical industry, are attempting to increase market demand by investing in research and development operations.
Novo Nordisk A/S, a well-known pioneer in the treatment of chronic illnesses including diabetes, has its global headquarters in Denmark. With a strong commitment to improving patient lives, Novo Nordisk focuses on the research, development, and marketing of innovative therapies. The company was founded in 1923 and has since developed into a major leader in the healthcare industry. Novo Nordisk's main areas of competence are the treatment of hemophilia, the management of diabetes, and the management of obesity. The company's broad line of pharmaceutical products includes insulin, GLP-1 receptor agonists, and other medications used to manage diabetic complications and control blood sugar levels. Novo Nordisk also conducts research and development on therapies for rare bleeding disorders including hemophilia.
An Indian biopharmaceutical business called Biocon Ltd. is dedicated to the development and production of novel, cost-effective therapies for a variety of therapeutic conditions. Biocon, which Kiran Mazumdar-Shaw founded in 1978, has developed into one of India's top biotechnology firms with a global presence and a dedication to providing affordable healthcare solutions.
Biopharmaceuticals, biosimilars, and innovative therapeutics are among Biocon's primary fields of competence. By creating biosimilar versions of complicated biologic medications, the business has significantly improved access to therapies for people all around the world. Oncology, immunology, and diabetes care medicines are all part of Biocon's portfolio of biosimilars.
Key Companies in the Insulin Syringes market include
3/10 CC Syringe (0.3ml)
1/2 CC Syringe (0.5ml)
1CC Syringe (1ml)
Others
Type 1 Diabetes
Type 2 Diabetes
Hospitals & Clinics
Homecare Settings
Others
North America
U.S.
Canada
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Australia
Rest of Asia-Pacific
Rest of the World
Middle East
Africa
Latin America
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)